These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25365225)

  • 1. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.
    Barbie TU; Alexe G; Aref AR; Li S; Zhu Z; Zhang X; Imamura Y; Thai TC; Huang Y; Bowden M; Herndon J; Cohoon TJ; Fleming T; Tamayo P; Mesirov JP; Ogino S; Wong KK; Ellis MJ; Hahn WC; Barbie DA; Gillanders WE
    J Clin Invest; 2014 Dec; 124(12):5411-23. PubMed ID: 25365225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.
    Zhu Z; Aref AR; Cohoon TJ; Barbie TU; Imamura Y; Yang S; Moody SE; Shen RR; Schinzel AC; Thai TC; Reibel JB; Tamayo P; Godfrey JT; Qian ZR; Page AN; Maciag K; Chan EM; Silkworth W; Labowsky MT; Rozhansky L; Mesirov JP; Gillanders WE; Ogino S; Hacohen N; Gaudet S; Eck MJ; Engelman JA; Corcoran RB; Wong KK; Hahn WC; Barbie DA
    Cancer Discov; 2014 Apr; 4(4):452-65. PubMed ID: 24444711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
    Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
    Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.
    Liu S; Marneth AE; Alexe G; Walker SR; Gandler HI; Ye DQ; Labella K; Mathur R; Toniolo PA; Tillgren M; Gokhale PC; Barbie D; Mullally A; Stegmaier K; Frank DA
    Blood Adv; 2018 Dec; 2(23):3428-3442. PubMed ID: 30504235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.
    Hu Y; Dong XZ; Liu X; Liu P; Chen YB
    Mol Pharm; 2016 Feb; 13(2):689-97. PubMed ID: 26685983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
    Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
    Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
    Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
    Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYT387, a potent IKBKE inhibitor, suppresses human glioblastoma progression by activating the Hippo pathway.
    Wang X; Lu J; Li J; Liu Y; Guo G; Huang Q
    J Transl Med; 2021 Sep; 19(1):396. PubMed ID: 34544426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated kinase screening identifies the
    Leonardi M; Perna E; Tronnolone S; Colecchia D; Chiariello M
    Autophagy; 2019 Feb; 15(2):312-326. PubMed ID: 30289335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sanguinarine Inhibition of TNF-α-Induced CCL2, IKBKE/NF-κB/ERK1/2 Signaling Pathway, and Cell Migration in Human Triple-Negative Breast Cancer Cells.
    Messeha SS; Zarmouh NO; Antonie L; Soliman KFA
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in IKBKE as a potential target for cancer therapy.
    Yin M; Wang X; Lu J
    Cancer Med; 2020 Jan; 9(1):247-258. PubMed ID: 31733040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ.
    Jin S; Mutvei AP; Chivukula IV; Andersson ER; Ramsköld D; Sandberg R; Lee KL; Kronqvist P; Mamaeva V; Ostling P; Mpindi JP; Kallioniemi O; Screpanti I; Poellinger L; Sahlgren C; Lendahl U
    Oncogene; 2013 Oct; 32(41):4892-902. PubMed ID: 23178494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial cells promote triple-negative breast cancer cell metastasis
    Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
    FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.
    Yang S; Imamura Y; Jenkins RW; Cañadas I; Kitajima S; Aref A; Brannon A; Oki E; Castoreno A; Zhu Z; Thai T; Reibel J; Qian Z; Ogino S; Wong KK; Baba H; Kimmelman AC; Pasca Di Magliano M; Barbie DA
    Cancer Immunol Res; 2016 Jun; 4(6):520-30. PubMed ID: 27068336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
    Matsumoto G; Namekawa J; Muta M; Nakamura T; Bando H; Tohyama K; Toi M; Umezawa K
    Clin Cancer Res; 2005 Feb; 11(3):1287-93. PubMed ID: 15709200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
    Boehm JS; Zhao JJ; Yao J; Kim SY; Firestein R; Dunn IF; Sjostrom SK; Garraway LA; Weremowicz S; Richardson AL; Greulich H; Stewart CJ; Mulvey LA; Shen RR; Ambrogio L; Hirozane-Kishikawa T; Hill DE; Vidal M; Meyerson M; Grenier JK; Hinkle G; Root DE; Roberts TM; Lander ES; Polyak K; Hahn WC
    Cell; 2007 Jun; 129(6):1065-79. PubMed ID: 17574021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer.
    Alraouji NN; Al-Mohanna FH; Ghebeh H; Arafah M; Almeer R; Al-Tweigeri T; Aboussekhra A
    Mol Carcinog; 2020 Sep; 59(9):1041-1051. PubMed ID: 32537818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.